Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature by Lacerda, Marcus VG et al.
REVIEW Open Access
Understanding the clinical spectrum of
complicated Plasmodium vivax malaria: a
systematic review on the contributions of the
Brazilian literature
Marcus VG Lacerda
1,2,3*, Maria PG Mourão
1,2,3, Márcia AA Alexandre
1,2,3, André M Siqueira
1,2,
Belisa ML Magalhães
1,2, Flor E Martinez-Espinosa
1,2,4, Franklin S Santana Filho
1,2, Patrícia Brasil
5, Ana MRS Ventura
6,
Mauro S Tada
7, Vanja SCD Couto
8, Antônio R Silva
9, Rita SU Silva
10 and Maria GC Alecrim
1,2,3
Abstract
The resurgence of the malaria eradication agenda and the increasing number of severe manifestation reports has
contributed to a renewed interested in the Plasmodium vivax infection. It is the most geographically widespread
parasite causing human malaria, with around 2.85 billion people living under risk of infection. The Brazilian Amazon
region reports more than 50% of the malaria cases in Latin America and since 1990 there is a marked
predominance of this species, responsible for 85% of cases in 2009. However, only a few complicated cases of P.
vivax have been reported from this region. A systematic review of the Brazilian indexed and non-indexed literature
on complicated cases of vivax malaria was performed including published articles, masters’ dissertations, doctoral
theses and national congresses’ abstracts. The following information was retrieved: patient characteristics
(demographic, presence of co-morbidities and, whenever possible, associated genetic disorders); description of
each major clinical manifestation. As a result, 27 articles, 28 abstracts from scientific events’ annals and 13 theses/
dissertations were found, only after 1987. Most of the reported information was described in small case series and
case reports of patients from all the Amazonian states, and also in travellers from Brazilian non-endemic areas. The
more relevant clinical complications were anaemia, thrombocytopaenia, jaundice and acute respiratory distress
syndrome, present in all age groups, in addition to other more rare clinical pictures. Complications in pregnant
women were also reported. Acute and chronic co-morbidities were frequent, however death was occasional.
Clinical atypical cases of malaria are more frequent than published in the indexed literature, probably due to a
publication bias. In the Brazilian Amazon (considered to be a low to moderate intensity area of transmission),
clinical data are in accordance with the recent findings of severity described in diverse P. vivax endemic areas
(especially anaemia in Southeast Asia), however in this region both children and adults are affected. Finally, gaps of
knowledge and areas for future research are opportunely pointed out.
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Background
Plasmodium vivax is the most geographically widespread
species of Plasmodium causing human disease, with most
cases reported in Central and Southeast Asia, in the horn
of Africa and in Latin America [1]. It is considered to be
a potential cause of morbidity and mortality amongst the
2.85 billion people living at risk of infection, excluding
the large African populations who are mostly Duffy nega-
tive and, therefore, naturally less susceptible to this infec-
tion. However recent data suggest that the parasite is
evolving and may use alternative receptors other than
Duffy (DARC) for erythrocyte invasion [2]. It is estimated
that 5.5% of the population under risk live in the Americas
[3]. The major biological characteristic of this parasite is
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any medium, provided the original work is properly cited.the presence of liver hypnozoites responsible for the fre-
quent relapses, which add a substantial number of cases to
the general burden of the disease, what is being faced as
one of the most challenging bottlenecks for vivax malaria
eradication [4].
Although often regarded as causing a benign infection,
there is recent increasing evidence that the overall bur-
den, economic impact, and severity of P. vivax have
been underestimated, in part due to a bias in the scienti-
fic literature which traditionally devoted most of its
attention to the more lethal parasite Plasmodium falci-
parum, probably as a reflection of a more substantial
funding [5]. Until 16 October 2011, the search in MED-
LINE using P. vivax as keyword retrieved 5,026 indexed
abstracts; using P. falciparum, on the other hand,
retrieved almost five times more abstracts: 25,807. Even
in places where P. vivax represents the major local pro-
blem to be tackled, clinical research is still focused on P.
falciparum [6]. There is robust evidence in the past dec-
ade from hospital-based studies in India and Indonesia
that P. vivax is able to cause severe disease [7,8]. Some
authors argue that this clinical severity may only now be
properly recognized and announced by researchers in
the field, but these complications apparently are not
new from a historical perspective [9]. Actually, the case
fatality rate (CFR) related to malarial infections in the
English marshes during the 16th and 17th centuries,
corresponding to the Little Ice Age, suggest that P.
vivax (a parasite more prone to persist in vectors even
under low temperatures) may have killed part of this
population already victimiz e db yf a m i n e[ 1 0 ] .D u r i n g
the first half of the 20th century, malariotherapy in
patients with neurosyphilis, using essentially the ‘non-
severe’ P. vivax parasite, led to diverse complications,
CFR ranging from 3.3 to 30.3% [11]. The major related
complications in these co-infected patients were liver
damage, ruptured spleen, jaundice, delirium, uncon-
trolled vomiting and persistent headaches [11]. That
reinforces the concept that P. vivax infection may syner-
gize with other co-morbidities resulting in more compli-
cated disease. Added to local geographical and social
determinants, wide Annual Parasite Incidence (API) and
CFR variations due to this species are seen around the
world.
In summary, P. vivax, which has long been neglected
and mistakenly considered ‘benign’ [12], is receiving an
increasing amount of importance in the debates taking
place on malaria epidemiology and control, drug resis-
tance, pathogenesis and vaccines [13]. As reviewed else-
where, the good clinical characterization of severe disease
in vivax infection is the first step to understand how the
inflammatory response to this parasite contributes to
pathogenesis [14].
Traditionally, Brazil has been responsible for almost
half of all cases of malaria in Latin America. In 2009,
308,498 cases of malaria were reported in this country
(257,571 caused by P. vivax), representing 54.9% of all
the malaria reported in the Americas [15]. Cases are
virtually restricted to the Amazon Basin (constituted by
the states of Amazonas, Acre, Roraima, Amapá, Pará,
Tocantins, Rondônia, and parts of Mato Grosso and
Maranhão). Amazonian urban agglomerations under
continuous economical development trigger intense
migration flows, such as in the city of Manaus (in the
Western Brazilian Amazon), helping to maintain the dis-
ease under endemic levels [16,17]. Malaria in Brazil is
mostly related to P. vivax since the 1990s, when the avail-
able tools for control at the moment were put together
and intensified, such as the fast diagnosis through thick
blood smear (TBS) in all febrile patients, and free access
to anti-malarials, integrated through a decentralized pri-
mary care-centred public health system [18]. Allied to
that, an active community of local malariologists has
been persistently identifying the profile of anti-malarial
resistance with permanent counseling to the Brazilian
Ministry of Health, which responds promptly to these
evidences, changing the first line regimens [19]. As the
sexual forms (which are infective for the vector) of P. fal-
ciparum generally appear later in the course of infection,
opportune diagnosis and treatment tend to have a high
impact on reducing the transmission intensity of this spe-
cies but the same is not true for P. vivax, whose gameto-
cytes are present in the very first days of the infection,
before efficacious treatment is usually started. In 2008,
59% of all malaria cases registered in the Brazilian Ama-
zon were treated in the first 48 h after appearance of
symptoms (SIVEP-Malaria, 2009). These public health
measures allied to a regularly updated online information
system also impacted the number of deaths related to
P. falciparum, which were not more than 58 in 2009
(Brazilian Ministry of Health, 2010). As a consequence,
even in the non-indexed literature, severity due to P. fal-
ciparum is not frequently reported anymore in Brazil.
Brazil has reported 85% of its cases related to P. vivax in
2010, which puts this country in a peculiar epidemiological
situation, as one of the few countries around the world
with P. vivax predominance. The impact of P. vivax/P. fal-
ciparum co-infections or simultaneous circulation of both
species with similar frequencies in a given population,
upon the immunological status and clinical presentation
of malaria is still unclear [20,21], but most probably clini-
cal data from population from certain areas should not be
extrapolated to other areas in distinct epidemiological con-
ditions. Actually, the lack of data on clinical presentation
of P. vivax infection allied to the several particularities of
this region, including the diverse genetic background of its
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ings from Southeast Asia may be inappropriate.
In Brazil, in 1903, the young physician Carlos Chagas
(most known for the discovery of American trypanosomia-
sis afterwards) wrote his MD thesis on the haematological
complications of malaria, which, at that moment, also
occurred in the non-Amazon area. His major findings in
studying P. vivax patients were severe anaemia, splenome-
galy, leukopenia, cachexia and jaundice associated to con-
comitant staphylococcal disease [22]. Bone marrows were
also analysed in these patients with no conclusive findings.
Later on, during the 1940s, Djalma Batista in Manaus
described a series of malarial cases from his outpatient
clinics in whom large splenomegaly, cachexia and minor
bleeding were frequent among those with the ‘benign’ ter-
tian malaria [23]. More recently, from 1998 to 2008, 234
deaths related to vivax disease were officially reported to
the Brazilian Ministry of Health [18], and an increase in
the hospitalization trends for vivax patients was published
in a tertiary care hospital from Manaus [24]. To compli-
cate matters, these facts parallel a lack of robust biomar-
kers and specific criteria for severe disease for this species
in the literature. A sine qua non requisite in the analysis of
clinical severity related to P. vivax infection is the exclu-
sion of mixed infection with P. falciparum through a more
sensitive technique such as PCR and the exclusion of
other co-morbidities which may be responsible for the
clinical presentation per se.I nt h el i t e r a t u r e ,i ng e n e r a l ,
reports of ‘complicated/severe’ cases lack more precise
and uniform definition criteria, in part due to the rare
application of more robust endpoints such as death and
admission to the intensive care unit (ICU), and therefore
end up suffering bias through individual judgment of
authors, editors and reviewers. As in most of the data pub-
lished there were no systematic exclusion of co-morbid-
ities and/or mono-infection confirmation using PCR,
performing a meta-analysis of severe manifestations of P.
vivax becomes virtually impossible. The other bias in the
case of Brazil is that many relevant data are confined in
abstracts from national scientific meetings and graduate
students’ dissertations and theses. The systematic review
of these unpublished data therefore could contribute to
the understanding of the clinical spectrum of vivax infec-
tion in this country and ultimately as a representative sam-
ple from Latin American vivax malaria.
Search strategy
The sources for published data on clinical aspects of vivax
infection in Brazil were MEDLINE (1948 to February
2011) and LILACS (1982 to February 2011). The following
search strategy was devised for both databases: (Plasmo-
dium vivax).mp. AND (Brazil).mp. All types of study
designs with primary data were included (cross-sectionals,
case-controls, cohorts, case series and case reports). The
abstracts were analysed in details by two independent
reviewers and publications were selected if they mentioned
any type of clinical complication (no specific criterion was
u s e d )i na tl e a s to n ep a t i e n twith the diagnosis of vivax
infection. Disagreement between the two reviewers was
solved through consensus. Articles were excluded if they
were reviews and also if they did not contain primary data
on clinical aspects. For included studies, there were
extracted data on date of publication, location, number of
patients, and characteristics of participants (age range,
pregnancy status, presence of co-morbidities), if molecular
diagnosis through PCR was used to assess vivax malaria
mono-infection and fatality. Exclusion criteria for analysis
were participants with mixed infections (P. falciparum/
P. vivax); studies in where patients with P. falciparum and
P. vivax were both presented but the clinical data reported
was not individualized for each species; and studies report-
ing the same patients from previous studies from the same
authors. Through abstract analysis, 297 articles were
retrieved and after application of the inclusion and exclu-
sion criteria, 27 articles (from 1987 to 2011) were selected,
which are presented in Table 1.
Unpublished studies were searched manually in the
Annals of the Congress of the Brazilian Tropical Medicine
Society (published in supplements of the indexed journal
Revista da Sociedade Brasileira de Medicina Tropical
[Journal of the Brazilian Society of Tropical Medicine]),
from 1964 to 2011. This is the most traditional scientific
event for tropical medicine clinicians in Brazil. Similar
inclusion and exclusion criteria were used in this search.
However if the same abstract data were published after-
wards as a full paper, the published paper information was
presented here. If the abstract referred to a dissertation or
thesis, this more detailed information was presented
instead. Forty-five abstracts were retrieved from 1995 to
2011. Of these, 17 fulfilled any of the exclusion criteria
and therefore, 28 abstracts are presented in Table 2.
Masters’ dissertations and doctoral theses abstracts
since 1987 were searched in the online database http://
capesdw.capes.gov.br/capesdw/Teses.do maintained by
the Coordination for the Improvement of Higher Educa-
tion Personnel (CAPES), the institution which coordi-
nates and supervises all the Brazilian Graduate
Programmes in all areas of knowledge. The full original
electronic documents were downloaded from the website
when available or obtained through contact with the
respective graduate students. Ten dissertations and three
theses are presented in Table 3.
Major clinical complications
Classical malaria paroxysms are typically short and shar-
ply delineated within a period of less than eight hours.
Fever is one feature that is almost invariably present
during a paroxysm. Any of other common symptoms of
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patients in Brazil (1948-2011)
Authors Year
of
publication
Location
City
(State)
PCR
confirmation
Age
range
(in
years)
Number
of
patients
Type of clinical
complication
Pregnancy Death Co-morbidity
1 Botelho et al.
[25]
1987 Cuiabá
(Mato
Grosso)
No NA 41 Pulmonary manifestations No No NA
2 Moura et al.
[26]
1987 NA No NA 1 Congenital malaria (?) No No NA
3 Severo et al.
[27]
1994 NA No NA 112 Hepatitis and jaundice No No NA
4 Marques et al.
[28]
1996 São Paulo
(São Paulo)
No 5
weeks
1 Congenital malaria and
anaemia
No No NA
5 Siqueira-
Batista et al.
[29]
1998 Rio de
Janeiro
(Rio de
Janeiro)
No 62 1 Cardiac arrhythmia after
chloroquine use
No No NA
6 Ventura et al.
[30]
1999 Belém
(Pará)
No 0-14 100 Anaemia No No Hookworms and
malnutrition
7 Pinheiro et al.
[31]
2002 Belém
(Pará)
No NA 23 Low birth weight Yes No NA
8 Jarude et al.
[32]
2003 Rio Branco
(Acre)
No 12-49 235 Anaemia, jaundice,
hepatitis and
hypoglycaemia
Yes No NA
9 Lacerda et al.
[33]
2004 Manaus
(Amazonas)
Yes 20 1 ITP No No No
10 Silva et al. [34] 2004 Belém
(Pará)
No 18-60 11 Blackwater fever after
primaquine use
No No G6PD deficiency
11 Melo et al.
[35]
2004 Manaus
(Amazonas)
No 7-84 126 Ocular lesions No No Hypovitaminosis
A
12 Braga et al.
[36]
2004 Fortaleza
(Ceará)
No 25 1 Neurological symptoms No No NA
13 Lomar et al.
[37]
2005 São Paulo
(São Paulo)
No 43 1 ARDS No No No
14 Vermehren et
al. [38]
2005 Manaus
(Amazonas)
No 51 1 Acute renal failure No No No
15 Braga et al.
[39]
2006 Coari
(Amazonas)
No 14-69 333 Hepatitis No No HBV
16 Cabral et al.
[40]
2006 Manaus
(Amazonas)
No 4 1 Blackwater fever, anaemia
and ARDS
No No Sickle cell
anaemia
17 Lacerda et al.
[41]
2007 Manaus
(Amazonas)
No 23 1 Splenic hematoma No No NA
18 Santana et al.
[42]
2007 Manaus
(Amazonas)
No 3-67 73 Methaemoglobinemia
after primaquine use
No No G6PD deficiency
19 Lacerda et al.
[43]
2008 Maués
(Amazonas)
Yes 14 1 Chronic splenomegaly and
thrombocytopaenia
No No NA
20 Ramos Jr et al.
[44]
2010 Manaus
(Amazonas)
No 8-39 18 Blackwater fever after
primaquine use
No No G6PD deficiency
21 Alexandre et
al. [45]
2010 Manaus
(Amazonas)
Yes 0-80 17 Jaundice, anaemia, shock,
acute renal failure, ARDS
and haemoglobinuria
No Yes
(1)
HAV,
hypertension
and diabetes
22 Siqueira et al.
[46]
2010 Manaus
(Amazonas)
Yes 16 1 Rhabdomyolysis No No No
23 Melo et al.
[47]
2010 Careiro
(Amazonas)
No 5-14 54 Anaemia No No Intestinal
helminthes
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24 Andrade et al.
[48]
2010 Buritis
(Rondônia)
Yes 9-54 19 Jaundice, anaemia, shock,
acute renal failure and
ARDS
No Yes
(6)
No
25 Chagas et al.
[49]
2010 Manaus
(Amazonas)
No 9-44 411 Vaginal bleeding and
amniorrexis
Yes No NA
26 Fragoso et al.
[50]
2011 Manaus
(Amazonas)
Yes 48 1 Hypovolaemic shock after
CQ use
No No Hemophilia A
27 Ferreira et al.
[51]
2011 Macapá
(Amapá)
No 15-60 20 Methaemoglobinemia
after primaquine use
No No G6PD deficiency
Table 2 Summary of abstracts referring to clinical aspects of P. vivax malarial patients published in the proceedings of
the Annual Congress of the Brazilian Society of Tropical Medicine (1964-2011)
Authors Year of
publication
Location
City
(State)
PCR
confirmation
Age
range
(in
years)
Number
of
patients
Type of clinical
complication
Pregnancy Death Co-morbidity
1 Alecrim et al.
[52]
1995 Manaus
(Amazonas)
No 26 2 Splenic haematoma
rupture
No Yes
(1)
NA
2 Kalmar et al.
[53]
1998 São Paulo
(São Paulo)
No 24 1 Pulmonary
manifestations
No No NA
3 Sardinha et
al. [54]
1998 Manaus
(Amazonas)
No 42/57 2 Auto-immune anaemia
induced by secondary
cryoagglutinins
No No NA
4 Victoria et al.
[55]
1998 Manaus
(Amazonas)
No 21 1 ITP No No NA
5 Zumpano et
al. [56]
1998 Belo
Horizonte
(Minas
Gerais)
No 40 1 Splenic haematoma
rupture
No No NA
6 Silva et al.
[57]
2000 Manaus
(Amazonas)
No NA 25 Thombocytopaenia and
bleeding
No No NA
7 Aragão et al.
[58]
2001 Manaus
(Amazonas)
No NA 50 Thombocytopaenia and
bleeding
No No NA
8 Evangelista et
al. [59]
2002 Manaus
(Amazonas)
No < 1
month
7 Congenital malaria
(jaundice and anaemia)
No No NA
9 Moura et al.
[60]
2002 Belo
Horizonte
(Minas
Gerais)
No 69 1 Acute lung oedema No Yes NA
10 Park et al.
[61]
2002 São Paulo
(São Paulo)
No NA 237 Thrombocytopaenia No No NA
11 Viana et al.
[62]
2002 Santa Inês
(Maranhão)
No 21 1 Pleural effusion No No NA
12 Albuquerque
et al. [63]
2003 Manaus
(Amazonas)
No NA 202 Anaemia,
thrombocytopaenia,
blackwater fever,
jaundice and bleeding
No No Yes (diabetes,
chronic renal
failure, HIV, G6PD
deficiency)
13 Lacerda et al.
[64]
2003 Manaus
(Amazonas)
Yes 46 1 Acute lung oedema No Yes NA
14 Silva et al.
[65]
2003 Belém
(Pará)
No 21 1 Acute lung oedema No No NA
15 Silva et al.
[66]
2004 Tucuruí
(Pará)
No 59 1 Vasculitis No Yes NA
16 Tavares et al.
[67]
2004 Manaus
(Amazonas)
No 12 1 Splenic haematoma No No NA
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the Annual Congress of the Brazilian Society of Tropical Medicine (1964-2011) (Continued)
17 Penna et al.
[68]
2005 Belo
Horizonte
(Minas
Gerais)
No 52 1 Pulmonary
manifestations
No No Yes (Dyslipidemia)
18 Mello et al.
[69]
2006 Belém
(Pará)
No NA 1 Seizures and coma No No NA
19 Menezes et
al. [70]
2006 Manaus
(Amazonas)
No 14-48 48 Abortion and
premature delivery
Yes No NA
20 Oliveira et al.
[71]
2006 Manaus
(Amazonas)
No 22 1 Blackwater fever after
primaquine use
No Yes Yes (G6PD
deficiency)
21 Bastos et al.
[72]
2007 Salvador
(Bahia)
No 28 1 Jaundice and
cholangitis
No No NA
22 Campos et al.
[73]
2007 São Paulo
(São Paulo)
No NA 1 Splenic haematoma
rupture
No No NA
23 Gurgel at al.
[74]
2007 Manaus
(Amazonas)
No < 3
months
5 Congenital malaria
(jaundice)
No No NA
24 Borzacov et
al. [75]
2008 Porto
Velho
(Rondônia)
No 33 1 Acute psychosis after
CQ use
No No NA
25 Cardoso et al.
[76]
2008 Porto
Velho
(Rondônia)
No 57 1 Leukemoid reaction No No NA
26 Ohnishi et al.
[77]
2008 Belém
(Pará)
No 29 1 Pulmonary
manifestations
No No NA
27 Menezes et.
al. [78]
2010 Manaus
(Amazonas)
No NA 421 Anaemia Yes No NA
28 Ohnishi et al.
[79]
2010 Belém
(Pará)
No > 15 83 Pulmonary
manifestations and TNF
and IL-12
polymorphisms
No No NA
Table 3 Summary of master dissertations and doctoral theses retrieved from CAPES referring to clinical aspects of
P. vivax malarial patients in Brazil (1948-2011)
Authors Year
of
publication
Location
City
(State)
PCR
confirmation
Age
range
(in
years)
Number
of
patients
Type of clinical
complication
Pregnancy Death Co-morbidity
1 Urbaez-Brito JD
[80]
1995 Costa
Marques
(Rondônia)
No NA 35 Jaundice No No HBV
2 Alecrim MGC [81] 2000 Manaus
(Amazonas)
Yes > 18 426 Thrombocytopaenia,
bleeding and DIC
No Yes
(1)
NA
3 Neves, JJO [82] 2002 Belém
(Pará)
No NA 127 Thrombocytopaenia No No NA
4 Marques HO [83] 2004 Manaus
(Amazonas)
No 15-75 106 Thrombocytopaenia
and coagulation
disorders
No No NA
5 Oliveira MS [84] 2004 Manaus
(Amazonas)
No 0-11 69 Anaemia No No Intestinal
helminthes
6 Silva IBA [85] 2004 Belém
(Pará)
No > 15 83 Thormbocytopaenia
and TNF
No No NA
7 Raposo CCBS [86] 2006 Buriticupu
(Maranhão)
No 1-70 140 Jaundice, anaemia,
thrombocytopaenia,
acute renal failure,
ARDS, bleeding and
neurological symptoms
No No No
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ing, are also described. These symptoms of a paroxysm
could be accompanied by others, including headache,
nausea and vomiting, and moderate to severe muscle,
joint and back pain [93]. Indeed high fever tends to be
more evident in vivax disease even with lower parasitae-
mia, due to its recognized lower fever-threshold (around
100 infected RBCs/microlitre) [94]. Therefore, any
description of these classical symptoms, together or iso-
lated, should be regarded by any experienced clinical as
non-severe malaria, regardless of their intensity, because
they are not associated to increased rates of hospitaliza-
tion or fatality.
In the Brazilian literature reviewed, a wide spectrum of
clinical complications aside from the classical symptoms
of vivax malaria was found throughout the 68 indexed and
non-indexed publications, despite the low number of
deaths attributed to this species in this literature sample.
The major complications are addressed as follows:
Anaemia
World Health Organization (WHO) criterion for severe
anaemia is haemoglobin below 5 g/dL in children and
under 7 g/dL in adults. However the clinical manifesta-
tions due to anaemia per se are not known and to what
extent it contributes to the respiratory distress associated
with the hyperdynamic status of the febrile syndrome.
There is scarce literature on malarial anaemia in popula-
tion-based studies in Latin America, as reviewed elsewhere
[95]. On top of that, major differences in Latin America
are seen when the same methodology is applied. That is
probably related to distinct genetic background and
environmental factors, e.g. in the Amazon Basin (intense
racial mixture) and in the Colombian Pacific Coast (non-
mixed black population) [96]. It is not known if anaemia is
as frequent among patients from Brazil as in Southeast
Asian patients, where P. vivax is considered to be a disease
of children because the acquisition of immunity against
this species occurs much faster than for P. falciparum,i n
highly endemic areas [97]. In Brazil only 25% of vivax dis-
ease affects children 0-14 years of age, however severe
anaemia was reported in hospitalized children and adults,
needing red blood cell (RBC) transfusions [45]. A key
description of anaemia in vivax malaria children in Latin
America was published in Venezuela in 2006 [98]. The
‘congenital malaria’ in newborns from the present series of
reports with severe anaemia confirms previous findings
that vivax malaria has an important clinical impact in chil-
dren under 3 months [99]. Non-severe anaemia, however,
seems to be as frequent as 25.8% among the population of
a recent occupation area in Rondônia, where hydroelectric
power plants are being built [100]. The cut-off of haemo-
globin under 12 g/dL as a criterion of anaemia however
should be seen with scepticism because of age ranges and
the lack of baseline levels of haemoglobin validated to spe-
cific populations, which makes meta-analyses susceptible
to misclassification. Major confounding factors in the glo-
bal analysis of anaemia are the local contributors to this
haematological complication such as iron-deficiency anae-
mia, which was found to occur in 5.6% of a rural Amazo-
nian population, mostly among school children and
women [101]. Another important associated condition,
which may interfere in the comparison between distinct
populations, is the prevalence of intestinal helminthic
Table 3 Summary of master dissertations and doctoral theses retrieved from CAPES referring to clinical aspects of
P. vivax malarial patients in Brazil (1948-2011) (Continued)
8 Pereira MSS [87] 2006 Manaus
(Amazonas)
No NA 76 Jaundice Yes No NA
9 Guerreiro NSV [88] 2006 Macapá
(Amapá)
No 25-39 35 Anaemia No No NA
10 Lacerda MVG [89] 2007 Manaus
(Amazonas)
Yes > 18 142 Thrombocytopaenia
and bleeding
No No No
11 Silva SBR [90] 2009 Cuiabá
(Mato
Grosso)
No NA 397 Thrombocytopaenia No No NA
12 Fragoso SCP [91] 2010 Manaus
(Amazonas)
Yes 1-88 17 Autopsies series (acute
lung oedema, shock,
blackwater fever, spleen
haematoma rupture)
No Yes
(17)
Pneumonia,
G6PD
deficiency,
chronic
hepatitis, HIV
and yellow
fever
13 Lança EFC [92] 2011 Manaus
(Amazonas)
No 0-14 24 Anaemia, shock, ARDS,
coma, jaundice,
blackwater fever,
metabolic acidosis and
hypoglycaemia
No Yes
(2)
Malnutrition,
gastroenteritis,
sepsis, G6PD
deficiency
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presence of hookworms and malnutrition was cited [30].
However some controversy exists regarding this influence
since in a cohort study, children with any intestinal hel-
minth were protected from anaemia triggered by acute
vivax infection [47]. In fact anti-helminthic treatment and
iron supplementation reduced the haematological indexes
in the population from an endemic area for malaria [102].
No Brazilian study has addressed the concomitant diagno-
sis of parvovirus B19 as a contributing factor to anaemia
in malaria, considering that recent evidence supports that
t h eu s eo fc h l o r o q u i n e( C Q )m a ys t i m u l a t ev i r a lr e p l i c a -
tion in the bone marrow, worsening anaemia [103].
Apparently pregnant women develop anaemia as a major
complication in vivax infection [32,78], and the impact
upon the concept needs further investigation. Chronic co-
morbidities affecting erythrocyte physiology, such as sickle
cell anaemia (SCA), may be related to more severe haemo-
lysis and severe anaemia as well [40].
Thrombocytopaenia and other coagulation disorders
Thrombocytopaenia as defined by platelet counts under
150,000/μL seems to be very frequent among patients
with vivax malaria and apparently more frequent in vivax
than in falciparum patients [104], despite not being a
consensus [105]. The increase in the report of thrombo-
cytopaenia in several reference centres could also be a
reflection of a better laboratorial infrastructure. Only in
recent decades in developing countries automated full
blood counts included platelet count as a routine. Many
studies in Brazil confirm that platelet counts are directly
correlated to peripheral parasitaemia [89,90], but the
meaning of this finding is still unknown. However, only
mild bleeding is usually associated with this haematologi-
cal complication in studies where detailed and systematic
clinical description of the patients was made, even for
severe thrombocytopaenia, which means in general plate-
let count under 50,000/μL [81,89,90]. In fact, there is no
report in the whole literature of a fatal case of patient
presenting exclusively with severe thrombocytopaenia,
even for P. falciparum. That is probably why thrombocy-
topaenia, regardless of being described as a complication
by WHO, is not strictly-speaking considered a severity
criterion by itself [106]. What happens most of the time
is that thrombocytopaenia is usually taken as a surrogate
marker for DIC in settings where no specific examina-
tions to confirm this severe complication are available,
such as prothrombin activation time, D-dimers and fibrin
degradation products. However, there is a disproportion-
ate difference in the proportions of thrombocytopaenia,
which is considered relatively frequent in large studies
for frequency estimation [90] and of DIC, which is a rare
complication, very scarcely reported in the literature
associated to P. vivax infection [107,108]. Actually, there
is some coagulation cascade activation, but usually with
minor impact on coagulation tests and platelet counts
[83]. It is important to consider however that in areas
where dengue is also endemic, as is the case of Brazil,
thrombocytopaenia studies should obligatorily rule out
this viral infection, which also presents a substantial per-
centage of thrombocytopaenia as part of its non-severe
presentation [109]. In fact there are cases of co-infection
already reported in the Brazilian Amazon recently [110],
but the literature poorly describes the clinical aspects of
this coincidental infection [111].
Respiratory distress and pulmonary oedema
Respiratory distress is defined by oxygen saturation less
than 94%, or deep breathing (acidotic breathing), or an
age-stratified increased rapid respiratory rate (> 32/min in
adults, > 40 in children 5-14 y, > 50 in children aged 2 mo
to 5 y, and > 60 in babies less than 2 mo)[112]. However
this syndromic approach does not translate any mechan-
ism of disease and may be associated to the clinical pre-
sentation of febrile syndrome during the malarial
paroxysm, severe anaemia, metabolic acidosis, lung
oedema, pneumonia or acute respiratory distress syn-
drome (ARDS). In most of the cited Brazilian studies,
there are no described criteria on how respiratory distress
was defined, which makes comparisons with the general
literature impossible. Sometimes imprecise clinical presen-
tation is simply defined as pulmonary manifestations. In
only one, ARDS is well characterized, comprising detailed
radiological characterization and arterial gas analysis
(FiO2/PaO2) [37]. Lung oedema is usually based on clinical
and radiological parameters and the effect of fluid overload
is not clear for vivax infection, since only a few cases were
reported so far, Brazilian cases included [39,64,65,
113,114]. The impairment of respiratory symptoms after
the beginning of treatment with CQ referred elsewhere
[115] was not mentioned in any of the present reports,
which could be due to inappropriate study design. Ruling
out pneumonia is not easy because of the low frequency of
positive blood cultures and due to the fact that in most of
these patients with pulmonary complications empirical
antibiotics are initiated as a rule. Data from the Papuan
Indonesia indicate that many infants who die with P. vivax
have radiological evidence of pneumonia [116], but the
specificity of radiological findings to differentiate vivax-
induced pulmonary abnormalities from pneumonia is
questionable. In Mozambique, pyogenic bronchopneumo-
nia was a common cause of respiratory distress in autop-
sied pregnant women with falciparum malaria, in both
HIV positive and negative [117]. In the Amazon, HIV pre-
valence is estimated to be ~1% (unpublished data), which
makes opportunistic diseases less prone to impact on
severe clinical complications of vivax malaria, as is the
case for falciparum malaria in Africa.
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This is classically the most lethal clinical complication of
severe falciparum malaria and the definition is also very
imprecise with a wide spectrum of possible presentations,
such as: impaired consciousness or unrousable coma
(Glasgow coma score ≤10 or Blantyre coma scale ≤2);
prostration, i.e. generalized weakness so that the patient
is unable walk or sit up without assistance; failure to
feed; or multiple convulsions (more than two episodes in
24 h). Despite being infrequent in our studies, the phe-
nomenon was also reported but not only in children
[36,86]. These reports must be very cautious in terms of
ruling out other malarial complications as the cause of
the neurological manifestations, such as hypoglycaemia
and metabolic acidosis, but also associated infections as
bacterial or viral meningoencephalitis. In India, acute
intermittent porphyria was an unexpected co-morbidity
associated to the neurological manifestations of patients
with vivax malaria [118]. In Papua, P. vivax-associated
coma was rare, occurring 23 times less frequently than
that seen with falciparum malaria, and was associated
with a high proportion of non-malarial causes and mixed
infections detected using PCR [119].
Acute renal failure
This complication is suspected in cases of oliguria and
confirmed if serum creatinine is higher than 3.0 mg/dL.
Bacterial sepsis, dehydration, shock and past history of
chronic renal failure should be routinely searched in the
differential diagnosis. It was also reported in the Brazilian
literature [38,48], but in one study one case was found in
a patient with arterial hypertension, what could be a trig-
gering condition [45]. Despite not being frequent in Bra-
zil, Plasmodium malariae is found in some scattered
areas [120], and as a potential cause of glomerulonephri-
tis [121], this parasite should be ruled out by molecular
biology tools whenever acute renal failure is detected in a
malarial patient with vivax infection, due to similarities of
these two species at routine optical microscopy.
Jaundice
New WHO guidelines already point to hyperbilirubinae-
mia (total bilirubin > 3.0 mg/dL) as being a weak marker
of severity, unless it is followed by any other vital organ
dysfunction [106]. This finding seems to be the most fre-
quent among children and adults with vivax disease con-
sidered as ‘severe’ [122,123]. Since haemolysis is not
usually as severe as to cause significant clinical jaundice,
most of these patients actually have some hepatocyte
necrosis as evidenced by the mild to moderate liver
enzymes (AST/ALT) increase with subsequent cholesta-
sis [124]. It was shown that icteric syndrome was a com-
mon cause of hospitalization in pregnant women with
vivax malaria in Manaus [87]. It was also detected in
newborns [59,74], which makes vivax malaria an obliga-
tory differential diagnosis of neonatal sepsis. Jaundice in
the presence of vomiting and upper abdominal pain
should raise suspicion on acalculous cholecystitis, a
poorly described complication apparently with good
prognosis [125]. Other diseases that may evolve to an
icteric syndrome may be ruled out, especially because
they are also more frequent in the tropics, such as leptos-
pirosis [34] and typhoid fever [126,127]. Hepatitis A virus
(HAV) and vivax co-infection has already been reported
as cause of jaundice and high elevation of transaminases
[45]. Hepatitis B virus (HBV) is also highly prevalent in
Brazil, especially in the Amazon [128] and there is some
evidence that P. vivax/HBV co-infection may be related
to more frequent jaundice [80] and higher transaminase
levels.
Algid malaria
Algid malaria refers to the shock syndrome usually defined
as circulatory collapse (systolic pressure under 70 mmHg
in adults or under 50 mmHg in children) non-responsive
to fluids. In the present vivax malaria reports, it was more
reported most frequently among patients who died, sug-
gesting that, as expected for this severe clinical complica-
tion, it could be regarded as a good marker of severity.
However, the aetiology of this complication is still unclear
even for P. falciparum. Apparently it is multifactorial and
the complication should be regarded as a syndrome where
cardiac dysfunction, dehydration, bleeding, adrenal insuffi-
ciency, and bacterial sepsis could all play a role [129]. A
review of all malaria deaths in the USA found that 5%
were due to P. vivax associated with cardiac disease [130],
which suggests cardiac dysfunction as a contributing factor
to algid malaria. There is robust evidence that bacteraemia
in Africa is associated with higher fatality in falciparum
malaria in children [131]. Less frequently shock occurs iso-
lated, but usually as part of multi-organ dysfunction syn-
drome (MODS), leading to a clinical picture suggestive of
‘malaria-induced toxic shock’ [132].
Metabolic complications
Metabolic acidosis (plasma bicarbonate < 15 mmol/L) and
hyperlactataemia (lactate > 5 mmol/L), which are common
in severe falciparum malaria and are good predictors of
fatal outcome, have never been described in vivax severe
disease. In a series of children with vivax infection
admitted to the ICU, metabolic acidosis is mentioned [92],
however concomitant sepsis is described in this series and
specificity for malaria cannot be assumed. If one admits
lactic acidosis as a consequence of hypoxia triggered by
microvasculature obstruction in falciparum disease, the
scarcity of data on the frequency of this phenomenon in
vivax disease may simply reflect the less severe obstruction
due to less cytoadhesion, as already suggested elsewhere
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40 mg/dL), the complication has been rarely described
elsewhere [123,135], and in only two studies in Brazil this
finding was reported among children and pregnant
women [32,92].
Pregnancy-associated malaria
The impact of vivax infection upon pregnancy and the
concept is less clear in Brazil and Latin America as a
w h o l e ,d e s p i t er o b u s te v i d e n c et h a tv i v a xm a l a r i ac a u s e s
low birth weight and maternal anaemia exists in Thailand
[136] and Indonesia [137]. The burden of the infection
due to this species in Brazilian pregnant women from a
h i g h l ye n d e m i ca r e ai nt h eA m a z o ns e e m st ob eh i g h
[138]. Malaria anaemia in pregnant women with vivax is
already known [137] and data from Brazil confirm that
this is the most common complication among these
women [78]. Additionally the few reports in the present
series also point to low birth weight, vaginal bleeding,
amniorrhexis, abortion, premature delivery, hypoglycae-
mia, hepatitis and jaundice as complications [31,32,49,
70,87]. Hyperemesis gravidarum may superimpose to the
f e b r i l es y n d r o m ea n dt ot h eg a s t r o i n t e s t i n a ls i d ee f f e c t s
associated to CQ in pregnant women, contributing to
uncontrolled vomiting and consequent metabolic disor-
ders. Apparently in the case of pregnancy, co-morbidities
do not seem to be frequent among patients with clinical
complications. Despite the need of more pathogenesis stu-
dies with the infected placenta, ultrasound studies in order
to search for prognostic markers are urgently needed.
Atypical complications
Some atypical complications are not frequently described
for malaria and likewise are not classically referred as
severe malaria. Rhabdomyolysis has been reported for
vivax in 1993 in a patient with myoadenylate deaminase
deficiency [139]; only one case was reported in Brazil in a
patient without co-morbidities [46]. Rarely, patients with
vivax malaria could evolve with immune thrombocytope-
nic purpura (ITP) as a complication of the acute infection
[33]. To confirm this diagnosis, the patient has to be fol-
lowed up with persistent thrombocytopaenia for many
weeks after the efficacious anti-malarial treatment and dis-
eases, in which ITP is more frequently seen, such as HIV,
should be discarded. The mechanisms involved are poorly
understood. Splenomegaly is considered a typical finding
in the physical examination of a patient with vivax disease,
but the occurrence of spleen haematomas evolving with
rupture and fatal outcome is relatively rare [41,52,91]
despite being more frequent among this species as com-
pared to falciparum [140]. In any case, patients with vivax
malaria referring abdominal pain should be investigated
for this complication as some patients may evolve with a
bad prognosis if not properly managed by a surgeon.
Ocular manifestations in vivax disease apparently have no
relation to cerebral malaria or bad prognosis, as is the case
for falciparum [141]. Few reports have been published on
vivax patients with non-severe disease and retinal haemor-
rhage [142] and in Brazil this fundoscopical finding was
associated with hypovitaminosis A [35]. Another atypical
complication, which may be more frequent than expected
for vivax infection, and with outstanding impact upon the
development of some emerging economies in the globe, is
poor school performance which should be a surrogate
marker for the intellectual impairment related to malaria
[143]. Acute malnutrition has been shown to be a compli-
cation of vivax malaria in highly endemic areas [144]. In
Brazil a few evidences show that malnourishment and
vivax co-exist but the impact of this association is still
unknown [145]. In only two studies was malnutrition
referred to as a possible cause of the reported clinical
complication [92,146]. Vasculitis [66], leukemoid reaction
[76] and pleural effusion [62] as a marker of severity
seems to be speculative and details of these reports do not
support any in-depth analysis.
Other aspects
High parasite density as a marker of severity for P. vivax,
as it is for P. falciparum, still needs additional studies, con-
sidering this parasite infects preferably reticulocytes. The
same occurs with the presence of schizonts in peripheral
blood, which is usually associated with high sequestered
biomass and severity for falciparum [147], but is still an
unexplored aspect for vivax. Strong linear trends were
identified regarding increasing plasma levels of C reactive
protein (CRP) and the gradation of disease severity [48].
Super-oxide dismutase-1 (SOD-1) seems to be a powerful
predictor of disease severity in individuals with different
clinical presentations of vivax malaria [148].
As soon as precise markers of severity are available, it
would be possible to design studies powered to analyse the
influence of the host genetics in the development of severe
vivax disease. Some association between pulmonary mani-
festations and TNF and IL-12 polymorphisms has been
attempted [79]. It has been proposed for the first time in
Manaus that G6PD deficiency could protect against vivax
malaria, in a cross-sectional study, based on past history of
the enrolled population [149]. This protection was later
confirmed in Pakistan [150]. Male hemizygotes for this
deficiency also showed to be protected against severe falci-
parum malaria [151]. No data exist on the protection
against severe vivax disease. Likewise, people with the
FYA/FYB genotype presented higher susceptibility to clini-
cal vivax malaria [152]. Since the discovery in Brazil that
Duffy-negative individuals could be infected by P. vivax
[153], some speculation on the other possible invasion
receptors has emerged. However, cohort studies are
needed to investigate the real impact of the distinct Duffy
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asymptomatic infection, malaria-triggered anaemia and
lower parasitaemia, as already suggested for FYB/FYX and
FYA/FYX genotypes in the Brazilian Amazon [154].
Advances in pathogenic mechanisms
T h em a j o ra d v a n c ei nt h es t u d yo ft h ep a t h o g e n e s i so f
severe vivax disease was the demonstration of P. vivax-
infected RBCs cythoadhesion on human lung endothelial
cells (HLEC) and placental tissue ex vivo [134]. This
cythoadhesion was obviously lower than P. falciparum-
infected RBCs adhesion, but with similar stability. How-
ever the next challenge is to try to link this finding to
the in vivo phenomena [155]. The increased adhesion
with the addition of LPS in the P. vivax ex vivo model
suggests that endothelial activation may be an enhancing
event. The role of augmented platelet-derived micropar-
ticles [156] and CD4
+CD25
+FoxP3
+ regulatory T cells
(Tregs) cells found in vivax disease should also be inves-
tigated in severe disease. Plasma levels of TNF, IFN-g
and also IFN-g/IL-10 ratios were increased and exhibited
a linear trend with gradual augmentation of disease
severity [48]. Patients with severe disease also presented
higher haemolysis and higher plasma concentrations of
Cu/Zn SOD-1 and lower concentrations of PGE-2 and
TGF-b than those with mild disease [157]. Oxidative
stress was also proposed as a mechanism for thrombo-
cytopaenia found in vivax disease [158,159], as well as
its association with TNF [85]. Circulating immune com-
plexes were not associated to vivax thrombocytopaenia
[89], but polymorphisms of the highly immunogenic
AMA-1 were associated to platelet count in these
patients [160], suggesting that immunological mechan-
isms are involved in platelet destruction. In the case of
anaemia, there is no correlation between the presence of
anti-erythrocyte and anti-cardiolipin antibodies and the
presence or intensity of this haematological finding
[161]. Auto-immunity induced by secondary cryoaggluti-
nins should be explored [54]. Erythropoiesis seems to be
affected [162], and the finding of parasites inside the
bone marrow [43] stimulate the search for mechanisms
of diserythropoiesis in this milieu, despite technical lim-
itations to analyse this tissue in humans. The role of the
spleen in severe disease is still unknown, as well as the
role of the variant subtelomeric multigene vir family,
which may influence the sequestration of infected RBCs
in this organ [163]. Parasite genetics, such as MSP-1
and CSP polymorphisms, has not been shown to be
associated with clinical severity [164].
In summary, the immune response in patients with
severe vivax disease has not been fully addressed in the
general literature, and further approaches are needed in
order to unveil immune mechanisms related to these
complications.
Vivax malaria therapy concerns
In terms of therapy, CQ and primaquine (PQ) are still the
drugs of choice for the treatment of vivax malaria in
many endemic areas, Brazil included. It is important
h o w e v e rt ok e e pi nm i n dt h a ts i d ee f f e c t so ft h e s ed r u g s
could be erroneously taken as clinical severity associated
to the parasite infection. In the case of CQ, it is consid-
ered a safe drug, despite the occurrence of pruritus,
which most of the time is considered to be a minor effect
and rarely requires the drug withdrawal [165]. Psychosis
on the other hand is a more severe complication
[75,166], as well as cardiac arrhythmia [29]. Atypical
complications of its use such as severe gastric bleeding
were associated with haemophilia A [50]. In the case of
PQ, tranquillity is not the same as with CQ, because PQ
is able to induce metahaemoglobinaemia [42,51] and
severe haemolysis [44] in patients with G6PD deficiency.
The burden of the deficiency in Brazil is poorly measured
but the few data available in endemic areas for malaria
has shown it to be between 3.0% [149] and 5.8% [167]
among men, since the deficiency is linked to the X-chro-
mosome. In the case of Brazil, the prescription of PQ in
the abbreviated regimen (0.5 mg/kg/day for 7 days) with-
out any routine G6PD screening may contribute to
increase the frequency and severity of the side effects
triggered by this drug, as confirmed by the reports of
patients with blackwater fever after PQ use, including
one fatal case [63,71,91,92,168]. To complicate matters,
for the radical cure, the new drug under late stage clinical
investigation, tafenoquine, shows no evidence that it is
safer than PQ in G6PD deficient [169].
The simultaneous occurrence of severe vivax disease and
CQ-resistance in some countries has raised the question of
a possible association between severity and resistance,
especially for anaemia [170]. CQ resistance actually has
been reported in Brazil almost at the same time as clinical
severity [171,172], but some studies argue against that,
showing that severe patients responded to CQ [45]. Added
to that, reliable genetic markers of resistance are lacking
[173]. Increased levels of pvmdr-1 and pvcrt-o RNA in a
single severe patient with vivax malaria however paved the
way to the study of gene expression in association to resis-
tance [174].
As suggested by the present data, 11 cases were
reported in Brazilian travellers who live in the non-ende-
mic area and occasionally go to the Amazon. Regarding
the possibility of severe disease triggered by P. vivax, Tra-
vel Outpatient Clinics should emphasize to their clients
the possible complications of this disease, still considered
‘benign’ in most of the educational folders and travellers’
guides, especially because no good chemoprophylaxis
against relapses related to this species is available to date.
On top of that, retarded diagnosis and treatment outside
the Amazon area contributes to the higher fatality rate of
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observed for P. vivax, being this disease misdiagnosed as
other febrile diseases.
Despite the increasing evidence of CQ-resistance
worldwide, the Brazilian Ministry of Health still recom-
mends CQ as the first line therapy for vivax treatment,
considering that only one single study has properly
shown ~10% of resistance in the area of Manaus [172].
The few available efficacy studies on ACT for the treat-
ment of vivax were reviewed recently [175], and give
good evidence for their use in vivax malaria, however,
more studies are needed. Only recently the Brazilian
Ministry of Health followed the WHO recommenda-
tions to manage vivax severe patients with parenteral
artemisinin derivatives as if they had severe falciparum
infection, considering that a submicroscopic mixed
infection could be misdiagnosed in the routine TBS
[106]. This recommendation was already stated by the
famous Brazilian parasitologist Samuel Pessôa in his
Medical Parasitology textbook, from 1967 [176]. Sup-
portive therapy is even more neglected and there is vir-
tually no study focusing in the clinical management of
patients with severe vivax disease.
Research priorities
There are actually many priorities in clinical research
related to vivax disease. The major ones were discussed
previously. Considering that asymptomatic infections
due to P. vivax are even more common in endemic
areas for both species [177], the likelihood of an asymp-
tomatic patient becoming ill due to another microorgan-
ism is not improbable, which requests a good
epidemiological characterization of the endemic area
where the severe cases are being reported and systema-
tic exclusion of mixed infections through PCR, due to
the possibility of submicroscopic infection with P. falci-
parum. Another major priority in vivax research is the
investigation of concurrent infections through systematic
laboratory exclusion of the most prevalent infectious
diseases in severe patients. In Figure 1, the major
research questions are addressed.
Conclusions
In the present systematic review, the major limitation was
t h ef a c tt h a tm o s to ft h ei n f o r m a t i o nw a sr e t r i e v e df r o m
non-peer reviewed sources. However, it seems clear that
vivax patients in Brazil are calling the attention of their
physicians only recently. Like other infectious diseases,
defining severity criteria is a major challenge. As an
example, dengue fever specialists have defined ‘warning
signs’ for dengue haemorrhagic fever, the most lethal
complication of the infection due to dengue virus, which
are early signs that should raise the suspicion of severe
dengue but are not applied themselves to the final classi-
fication [178] as proper intervention can avoid the
patient evolving to more severe stages. Sometimes in the
literature potential ‘warning signs’ for severe vivax
malaria are mistaken for severity criteria, which are those
ultimately related to increased fatality. WHO severity cri-
teria formerly developed for falciparum disease seem to
apply reasonably to vivax disease as well, but there are
clearly ‘warning signs’ that should motivate clinicians
from the tropics to observe patients more closely, such as
isolated thrombocytopaenia, isolated jaundice or the pre-
sence of chronic or acute co-morbidities. For example,
during influenza outbreaks, the virus does not necessarily
kill per se, but compromises the most vulnerable popula-
tion and facilitates fatal secondary bacterial infections.
The most common complications observed in the field
are not necessarily the most frequently reported in the
literature, sometimes biased by the uniqueness or exotic-
ness of the cases reported. It is only after 1987 that these
cases started to be reported in Brazil in indexed and non-
indexed publications, which may simply parallel the
increase in the absolute numbers of vivax cases in Brazil,
culminating in the more frequent observation of rare
clinical events triggered by this parasite. Publication bias
may also impact the chronology of these complicated
case reports, especially when research group leaderships
based in the endemic areas start to look for clinical
aspects more closely. It is noteworthy however that stu-
dies on pathogenesis must be careful when dealing with
severe vivax disease as a single entity. The best approach
is to study groups of patients with specific complications
(e.g., severe anaemia or ARDS) in order to minimize the
risk of heterogeneous groups with probable multifactor
causality, including the diversity of host genetics. The
amount of complications related to anti-malarial drug
use is not negligible, especially primaquine. Multicentric
studies using standard protocols, with the proper care of
confirming mono-infection by more specific tools (e.g.
PCR) and ruling out co-morbidities, are urgently needed
to characterize the real spectrum of vivax disease world-
wide. Tissues from deceased patients are also waited, in
order to support more robust analyses of the mechanisms
of death. Without that information, vaccine clinical trials
against P. vivax will not be able to include among their
endpoints the protection against the severe disease
(essentially severe anaemia), which parallels the fre-
quency of severe falciparum anaemia in some endemic
areas. The recent discussion on malaria eradication will
only succeed if the two parasites which most affect
humans begin to be treated as distinct and not causing a
single disease. Clinical characterization is the first step to
estimate its burden and ultimately to plan any control
strategy in the near future.
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Epidemiology  
1.  What is the real incidence of severe disease in population-
based studies in Latin America? 
2.  Is the incidence of severe disease similar in distinct 
epidemiological scenarios? And what is the impact of the 
health system organization on this severity? 
3.  What is the prognosis and fatality rate of severe disease in 
hospitalized and non-hospitalized patients? 
4.  What is the role of host genetics (e.g. Duffy genotypes, 
G6PD deficiency) upon severity?  
Clinical aspects 
1. Do the WHO criteria for severe P. falciparum malaria also 
apply for P. vivax severe disease? 
2. Which clinical complications are able to predict death? 
3. What is the contribution of co-morbidities to severe 
disease? 
4. What is the contribution of concurrent infections (bacterial, 
viral, fungal, parasitic) to severe disease? 
5. Are there specific severity presentation in some groups, e.g. 
pregnant women and children? 
6. Which are the bad prognostic findings in obstetric 
ultrasounds in pregnant women with malaria? 
7. What is the burden of clinical complications related more to 
drugs’ side effects? 
Pathogenesis 
1.  Which are the microscopic findings of autopsies from 
patients who died with the diagnosis of vivax infection? 
2.  Do all the clinical complications, classified as ‘severe’, 
share the same mechanisms of disease? 
3.  Is severe disease linked to the existing evidence of ex vivo 
cytoadhesion of P. vivax infected RBCs? What triggers 
endothelial activation? 
4.  Which are the best biomarkers for severity? 
Therapeutic aspects 
1.  Is clinical severity linked to CQ-resistance? 
2.  What should be the standard-of-care specific treatment for 
severe patients in areas where CQ-resistance is not high? 
3.  Antibiotics should be used systematically in which severe 
complications? 
4.  What type of adjunctive treatment should be initiated? 
 
Figure 1 Major research priorities in the study of severe vivax disease.
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